Works by Mamonov, V. V.

Results: 15
    1
    2
    3
    4
    5
    6
    7

    Efficacy and safety of a recombinant factor IX (Bax326)<sup>a</sup> in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.

    Published in:
    Haemophilia, 2014, v. 20, n. 5, p. 651, doi. 10.1111/hae.12419
    By:
    • WINDYGA, J.;
    • LISSITCHKOV, T.;
    • STASYSHYN, O.;
    • MAMONOV, V.;
    • GHANDEHARI, H.;
    • CHAPMAN, M.;
    • FRITSCH, S.;
    • WONG, W.-Y.;
    • PAVLOVA, B. G.;
    • ABBUEHL, B. E.
    Publication type:
    Article
    8
    9

    Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.

    Published in:
    Haemophilia, 2014, v. 20, n. 1, p. 15, doi. 10.1111/hae.12228
    By:
    • Windyga, J.;
    • Lissitchkov, T.;
    • Stasyshyn, O.;
    • Mamonov, V.;
    • Rusen, L.;
    • Lamas, J. L.;
    • Oh, M.‐S.;
    • Chapman, M.;
    • Fritsch, S.;
    • Pavlova, B. G.;
    • Wong, W.‐Y.;
    • Abbuehl, B. E.
    Publication type:
    Article
    10
    11
    12
    13
    14
    15